We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Explains How Amendments May Affect PDUFA Timelines

FDA Explains How Amendments May Affect PDUFA Timelines

September 2, 2014

The FDA has shed light on how amendments to an NDA, BLA or supplement may affect review timelines established under the 2012 prescription drug user fee program.

When any amendment to an application is received, the regulatory project manager (RPM), CDER division director and cross-discipline team leader first will determine whether it qualifies as a major amendment that requires a formal staff review, according to a new internal staff Manual of Policy and Procedures (MAPP) released last week.

If a review of the amendment is initiated, the FDA will then determine whether it will affect the deadline goal for making a decision on the product, said the document, which replaces a 2008 MAPP to reflect the PDUFA V review timelines established in the 2012 FDA Safety and Innovation Act. 

Under the reauthorized user fee program, CDER agreed to notify applicants of planned review timelines for new NDAs, BLAs and supplements. If the amendment extends the review timeline, then the RPM will notify the sponsor of the change and PDUFA goal date, the FDA said.

In rare cases, a major amendment may not extend the PDUFA date, but it could affect the review timeline. The RPM, team leader and division director must decide whether the original timeline will be retained or if a new one is needed, the FDA said. The RPM is responsible with notifying the applicant of any changes to the review timeline and that the PDUFA goal date is unchanged.
Minor amendments won’t affect the timeline.

The MAPP also notes that RPMs must notify the sponsor via a letter if serious problems with the application prevent discussion of labeling or postmarketing requirements or commitments.
The MAPP is available at www.fdanews.com/ext/resources/files/08/8-26-14-ReviewMAPP.pdf. — Robert King

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing